163 related articles for article (PubMed ID: 20120033)
1. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
Bhatt RS; Merchan J; Parker R; Wu HK; Zhang L; Seery V; Heymach JV; Atkins MB; McDermott D; Sukhatme VP
Cancer; 2010 Apr; 116(7):1751-6. PubMed ID: 20120033
[TBL] [Abstract][Full Text] [Related]
2. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
Gasparini G; Meo S; Comella G; Stani SC; Mariani L; Gamucci T; Avallone A; Lo Vullo S; Mansueto G; Bonginelli P; Gattuso D; Gion M
Cancer J; 2005; 11(3):209-16. PubMed ID: 16053664
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H; Polyzos A; Stavrinidis I; Frangia K; Tsoutsos D; Panagiotou P; Markopoulos C; Papadopoulos O; Pectasides D; Mantzourani M; Middleton M; Vaiopoulos G; Fountzilas G
Ann Oncol; 2006 Dec; 17(12):1835-41. PubMed ID: 16980601
[TBL] [Abstract][Full Text] [Related]
4. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Croghan GA; Suman VJ; Maples WJ; Albertini M; Linette G; Flaherty L; Eckardt J; Ma C; Markovic SN; Erlichman C
Cancer; 2010 Jul; 116(14):3463-8. PubMed ID: 20564112
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
Perez DG; Suman VJ; Fitch TR; Amatruda T; Morton RF; Jilani SZ; Constantinou CL; Egner JR; Kottschade LA; Markovic SN
Cancer; 2009 Jan; 115(1):119-27. PubMed ID: 19090009
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.
El Bary NA; Hashem T; Metwally H; Ghany AA; El Mageed HA
Hematol Oncol Stem Cell Ther; 2010; 3(1):13-8. PubMed ID: 20231809
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
Fruehauf JP; El-Masry M; Osann K; Parmakhtiar B; Yamamoto M; Jakowatz JG
Cancer Chemother Pharmacol; 2018 Aug; 82(2):353-360. PubMed ID: 29943192
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
[TBL] [Abstract][Full Text] [Related]
11. Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
Steinbild S; Arends J; Medinger M; Häring B; Frost A; Drevs J; Unger C; Strecker R; Hennig J; Mross K
Onkologie; 2007 Dec; 30(12):629-35. PubMed ID: 18063875
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
Altorki NK; Keresztes RS; Port JL; Libby DM; Korst RJ; Flieder DB; Ferrara CA; Yankelevitz DF; Subbaramaiah K; Pasmantier MW; Dannenberg AJ
J Clin Oncol; 2003 Jul; 21(14):2645-50. PubMed ID: 12860939
[TBL] [Abstract][Full Text] [Related]
14. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
Chang W; Lee SJ; Park S; Choi MK; Hong JY; Kim YS; Maeng CH; Jung HA; Kim S; Lee J
Melanoma Res; 2013 Apr; 23(2):147-51. PubMed ID: 23411477
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma.
Nathan FE; Berd D; Sato T; Mastrangelo MJ
Cancer; 2000 Jan; 88(1):79-87. PubMed ID: 10618609
[TBL] [Abstract][Full Text] [Related]
16. PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.
Coupe N; Corrie P; Hategan M; Larkin J; Gore M; Gupta A; Wise A; Suter S; Ciria C; Love S; Collins L; Middleton MR
Eur J Cancer; 2015 Feb; 51(3):359-66. PubMed ID: 25542057
[TBL] [Abstract][Full Text] [Related]
17. An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.
Thurneysen S; Cheng PF; Nagel HW; Kunz M; Jaberg-Bentele N; Nägeli M; Ziegler M; Guenova E; Goldinger SM; Mangana J; Levesque MP; Dummer R
Br J Dermatol; 2016 Nov; 175(5):966-978. PubMed ID: 27168024
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Dragovich T; Burris H; Loehrer P; Von Hoff DD; Chow S; Stratton S; Green S; Obregon Y; Alvarez I; Gordon M
Am J Clin Oncol; 2008 Apr; 31(2):157-62. PubMed ID: 18391600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]